Igm Biosciences Inc IGMS

$1.27 -0.03 (-2.31%)

Valuation

Market cap
76,572,000
Revenue TTM
$2,680,000
Net income TTM
$-195,800,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-7,305.97%
Debt to equity
0.00

Trading

Volume
1,618,900
Avg volume
740,806
Day's range
$1.27 – $1.30
Shares out
60,293,000
Stochastic %K
25%
Beta
0.60
Analysts
Hold
Price target
$1.41

Price

Company profile

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subs...

Show more

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Industry
Biotechnology
Sector
Healthcare
Phone
650 965 7873
Website
https://igmbio.com
Address
325 East Middlefield Road, Mountain View, United States

Latest news

Stocktwits

TheRealShortSqueezy Jan 12, 8:40 PM
$HYFT: Cup & Handle Breakout in Play 🚨‼️ MindWalk Holdings Corp is forming a classic cup and handle pattern, a bullish setup that often signals trend continuation. After an extended consolidation, price has reclaimed key resistance in the $2.50–$2.65 zone, suggesting renewed strength. Technical highlights: 📈Clear cup and handle formation on the daily chart 📈Breakout above prior resistance with solid follow-through 📈Higher-low structure signaling improving demand 📈Measured move upside targets near $3.60 → $4.40 → $4.90 Adding to the setup, MindWalk announced a share repurchase program on Oct 9, 2025, a shareholder-friendly catalyst that could help tighten supply as price approaches higher levels. If volume continues to support the move, HYFT may be entering a new bullish leg, with momentum traders watching closely as the pattern develops. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $CRSP $IGMS $ANTX $CABA
1 replies
TheRealShortSqueezy Jan 12, 2:21 PM
📌 $HYFT : Weekly Chart Setting Up for Expansion MindWalk holdings is pressing into key weekly resistance near $3.25, aligning with the cup level on the weekly timeframe and signaling growing upside potential. 🔍 Weekly structure highlights: 🔹 Price is firmly challenging the $3.25 weekly cup level 🔹 Strong recovery from long term lows with clear higher-low structure 🔹 Momentum accelerating as price moves through the base 🎯 Upside levels in focus as momentum builds: 📈 $3.65 📈 $4.00 📈 $4.40 📈 $4.90 📈 $5.43 📈 $5.90–$6.50 zone A sustained push through $3.25 on the weekly sets the stage for a broader move higher, with the chart offering clear expansion potential into upper resistance bands. Positive market reaction to recent breakthroughs reinforces HYFT’s positioning as a potential platform winner in the multi billion dollar influenza vaccine market. Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $IGMS $ANTX $CABA $ENTX
0 replies
TheRealShortSqueezy Dec 15, 3:26 PM
$HYFT: Riding the AI Biotech Wave Into Its Next Stage of Growth With AI fueling a new era of biotech breakthroughs, MindWalk is perfectly positioned, merging deep tech and biology to accelerate discoveries the entire sector has been waiting for. 📞 Conference Call Coming Up As the call approaches, investors are looking for clarity on HYFT’s accelerating momentum. Key topics expected to be discussed include: ➖ Record Q2 revenue growth and margin expansion ➖ Updates on the GLP-1 + longevity programs and dengue vaccine progress ➖ Strategic direction heading into the mid-January JPM update 💰 Strengthened by September’s Strategic Move On Sept 15, MindWalk sold its Netherlands operations, unlocking over $14M. That capital is now being directed into HYFT’s core BioNative AI platform and wet lab programs. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $FATE $IGMS $ANTX $CABA
1 replies
TheRealShortSqueezy Dec 15, 1:47 PM
$HYFT: RECORD Growth + Big Pipeline Wins Just Dropped 🗞️📰 MindWalk Holdings Corp just delivered its strongest quarter yet, combining major financial momentum with breakthrough AI driven pipeline progress. 📈 Financial Highlights: ➖ Revenue $4.1M (+54% YoY, +30% QoQ) ➖Gross margin 65% (up from 51%) ➖Gross profit +94% YoY ➖ $16.5M cash for platform + pipeline expansion 🧬 Pipeline Highlights: ➖ GLP-1: AI-designed agonist outperforming semaglutide ➖ Added longevity pathway → dual-pathway metabolic program 💥 Strategic Progress: ➖ Rebrand completed + new CFO/CBO ➖ Netherlands sale → $14.3M redirected to AI + wet lab programs 🔥 Next Catalyst: ➖ Mid-January pipeline + partnership update at JPM Healthcare Conference Record growth, stronger margins, and a loaded pipeline, $HYFT’s momentum is accelerating fast. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $IGMS $ANTX $CABA $ENTX
0 replies
smartkarma Oct 26, 8:15 PM
$IGMS | Primer: IGM Biosciences Inc (IGMS US) - Oct 2025 "IGM Biosciences is a clinical-stage biotechnology company centered on a proprietary platform for developing engineered Immunoglobulin M (IgM)..." - αSK (Smartkarma) Read more: https://www.smartkarma.com/insights/primer-igm-biosciences-inc-igms-us-oct-2025
0 replies
FreeBeerTomorrow Aug 14, 7:48 AM
$IGMS IGM Biosciences (IGMS) stock has been halted in anticipation of a merger with Concentra Biosciences. The tender offer for the acquisition is set to expire, and the merger is expected to close soon. Trading was halted at the end of the after-hours session on August 13, 2025, and will remain halted on August 14, 2025, with the stock being suspended from trading effective August 15, 2025.
0 replies
Mergerbrief Aug 13, 12:10 PM
$IGMS / Concentra Biosciences - Tender Offer Expires MergerBrief.com For Full Schedule Of Events
0 replies
TwongStocks Aug 12, 7:56 PM
$IGMS NASDAQ Equity Corporate Actions Alert # 2025 - 436 Information Regarding the Tender Offer of IGM Biosciences, Inc. (IGMS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-436 The tender offer by Concentra Biosciences to acquire all of the outstanding common stock of IGM Biosciences, Inc. (IGMS) is scheduled to expire one minute after 11:59 p.m. ET on August 13, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on August 14, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on August 13, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (August 14) and will be suspended effective August 15, 2025. Tender offer: $1.247 for each IGMS share held plus one non-tradeable contingent value right (CVR).
0 replies